After Apellis deal, Biogen looks to fill early-stage pipeline

April 29, 2026 11:15 AM EDTUpdated 12:58 PM DealsR&D Af­ter Apel­lis deal, Bio­gen looks to fill ear­ly-stage pipeline Lei Lei Wu News Reporter Bio­gen is still look­ing at deals even af­ter ear­mark­ing $5.6 bil­lion to buy Apel­lis Phar­ma­ceu­ti­cals ear­li­er this month. “Most of what we’re go­ing to be … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER